129 related articles for article (PubMed ID: 38417442)
21. Low-dose interleukin-2 promotes STAT-5 phosphorylation, T
Jeffery HC; Jeffery LE; Lutz P; Corrigan M; Webb GJ; Hirschfield GM; Adams DH; Oo YH
Clin Exp Immunol; 2017 Jun; 188(3):394-411. PubMed ID: 28176332
[TBL] [Abstract][Full Text] [Related]
22. A deubiquitination module essential for T
Montauti E; Weinberg SE; Chu P; Chaudhuri S; Mani NL; Iyer R; Zhou Y; Zhang Y; Liu C; Xin C; Gregory S; Wei J; Zhang Y; Chen W; Sun Z; Yan M; Fang D
Sci Adv; 2022 Nov; 8(47):eabo4116. PubMed ID: 36427305
[TBL] [Abstract][Full Text] [Related]
23. Tumor-infiltrating regulatory T cells, CD8/Treg ratio, and cancer stem cells are correlated with lymph node metastasis in patients with early breast cancer.
Solis-Castillo LA; Garcia-Romo GS; Diaz-Rodriguez A; Reyes-Hernandez D; Tellez-Rivera E; Rosales-Garcia VH; Mendez-Cruz AR; Jimenez-Flores JR; Villafana-Vazquez VH; Pedroza-Gonzalez A
Breast Cancer; 2020 Sep; 27(5):837-849. PubMed ID: 32180141
[TBL] [Abstract][Full Text] [Related]
24. AMP-activated protein kinase alpha1 promotes tumor development via FOXP3 elevation in tumor-infiltrating Treg cells.
An J; Ding Y; Yu C; Li J; You S; Liu Z; Song P; Zou MH
iScience; 2022 Jan; 25(1):103570. PubMed ID: 34988407
[TBL] [Abstract][Full Text] [Related]
25. PTEN-deficient prostate cancer is associated with an immunosuppressive tumor microenvironment mediated by increased expression of IDO1 and infiltrating FoxP3+ T regulatory cells.
Vidotto T; Saggioro FP; Jamaspishvili T; Chesca DL; Picanço de Albuquerque CG; Reis RB; Graham CH; Berman DM; Siemens DR; Squire JA; Koti M
Prostate; 2019 Jun; 79(9):969-979. PubMed ID: 30999388
[TBL] [Abstract][Full Text] [Related]
26. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
[TBL] [Abstract][Full Text] [Related]
27. Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.
Muroyama Y; Nirschl TR; Kochel CM; Lopez-Bujanda Z; Theodros D; Mao W; Carrera-Haro MA; Ghasemzadeh A; Marciscano AE; Velarde E; Tam AJ; Thoburn CJ; Uddin M; Meeker AK; Anders RA; Pardoll DM; Drake CG
Cancer Immunol Res; 2017 Nov; 5(11):992-1004. PubMed ID: 28970196
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of Regulatory T Cell-Related Markers (FOXP3, CTLA-4 and GITR) by Peripheral Blood Mononuclear Cells from Patients with Breast Cancer.
Khalife E; Khodadadi A; Talaeizadeh A; Rahimian L; Nemati M; Jafarzadeh A
Asian Pac J Cancer Prev; 2018 Nov; 19(11):3019-3025. PubMed ID: 30484986
[TBL] [Abstract][Full Text] [Related]
29. N6-methyladenosine-modified circular RNA QSOX1 promotes colorectal cancer resistance to anti-CTLA-4 therapy through induction of intratumoral regulatory T cells.
Liu Z; Zheng N; Li J; Li C; Zheng D; Jiang X; Ge X; Liu M; Liu L; Song Z; Bao L; Zhan Y; Gao X
Drug Resist Updat; 2022 Dec; 65():100886. PubMed ID: 36370665
[TBL] [Abstract][Full Text] [Related]
30. Effects of lactate on metabolism and differentiation of CD4
Zhang YT; Xing ML; Fang HH; Li WD; Wu L; Chen ZP
Mol Immunol; 2023 Feb; 154():96-107. PubMed ID: 36621062
[TBL] [Abstract][Full Text] [Related]
31. Preferential Expansion of Foxp3
Stohl W; Yu N; Wu Y
Immunohorizons; 2022 Jul; 6(7):507-514. PubMed ID: 35878937
[TBL] [Abstract][Full Text] [Related]
32. Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells.
Tekguc M; Wing JB; Osaki M; Long J; Sakaguchi S
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301886
[TBL] [Abstract][Full Text] [Related]
33. Analysis of CD8+ Treg cells in patients with ovarian cancer: a possible mechanism for immune impairment.
Zhang S; Ke X; Zeng S; Wu M; Lou J; Wu L; Huang P; Huang L; Wang F; Pan S
Cell Mol Immunol; 2015 Sep; 12(5):580-91. PubMed ID: 26166762
[TBL] [Abstract][Full Text] [Related]
34. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
Ohue Y; Nishikawa H
Cancer Sci; 2019 Jul; 110(7):2080-2089. PubMed ID: 31102428
[TBL] [Abstract][Full Text] [Related]
35. Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis.
Bonelli M; Göschl L; Blüml S; Karonitsch T; Hirahara K; Ferner E; Steiner CW; Steiner G; Smolen JS; Scheinecker C
Rheumatology (Oxford); 2016 Apr; 55(4):710-20. PubMed ID: 26672908
[TBL] [Abstract][Full Text] [Related]
36. Retinal pigment epithelium-derived CTLA-2alpha induces TGFbeta-producing T regulatory cells.
Sugita S; Horie S; Nakamura O; Futagami Y; Takase H; Keino H; Aburatani H; Katunuma N; Ishidoh K; Yamamoto Y; Mochizuki M
J Immunol; 2008 Dec; 181(11):7525-36. PubMed ID: 19017942
[TBL] [Abstract][Full Text] [Related]
37. CTLA-4 promotes lymphoma progression through tumor stem cell enrichment and immunosuppression.
Chen Y; Li M; Cao J; Cai G; Li X; Liu Y; Chen W
Open Life Sci; 2021; 16(1):909-919. PubMed ID: 34553071
[TBL] [Abstract][Full Text] [Related]
38. Low expressions of PD-L1 and CTLA-4 by induced CD4
Zhao L; Zhou X; Zhou X; Wang H; Gu L; Ke Y; Zhang M; Ji X; Yang X
Cytokine; 2020 Sep; 133():155119. PubMed ID: 32535334
[TBL] [Abstract][Full Text] [Related]
39. Significance of regulatory T cells in cancer immunology and immunotherapy.
Sugiyama D; Hinohara K; Nishikawa H
Exp Dermatol; 2023 Mar; 32(3):256-263. PubMed ID: 36458459
[TBL] [Abstract][Full Text] [Related]
40. Molecular Markers of Regulatory T Cells in Cancer Immunotherapy with Special Focus on Acute Myeloid Leukemia (AML) - A Systematic Review.
Kaboli PJ; Zhang L; Xiang S; Shen J; Li M; Zhao Y; Wu X; Zhao Q; Zhang H; Lin L; Yin J; Wu Y; Wan L; Yi T; Li X; Cho CH; Li J; Xiao Z; Wen Q
Curr Med Chem; 2020; 27(28):4673-4698. PubMed ID: 31584362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
